Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$0.91 -0.6%	$0.86	$0.55 ▼ $1.66	$117.42M	0.9	751,006 shs	364,255 shs
BHST BioHarvest Sciences	$7.12 -0.8%	$6.77	$4.66 ▼ $7.86	$116.91M	0.65	15,250 shs	1,095 shs
ESLA Estrella Immunopharma	$0.88 +2.9%	$0.96	$0.63 ▼ $3.23	$31.68M	0.36	124,938 shs	2,532 shs
KRRO Korro Bio	$13.32 +5.2%	$13.46	$10.29 ▼ $98.00	$125.09M	2.43	107,735 shs	30,795 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	-2.33%	+7.98%	+10.15%	+51.21%	-34.66%
BHST BioHarvest Sciences	+1.84%	+0.56%	-0.28%	+27.76%	+717,999,900.00%
ESLA Estrella Immunopharma	-5.54%	-4.06%	-12.92%	-0.05%	-44.27%
KRRO Korro Bio	-2.39%	-6.77%	-6.50%	-5.94%	-74.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Genetics	3.1476 of 5 stars	3.7	4.0	0.0	0.0	3.8	1.7	0.0
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	3.1301 of 5 stars	3.5	5.0	0.0	0.0	3.3	1.7	0.0
KRRO Korro Bio	1.5125 of 5 stars	3.6	1.0	0.0	0.0	1.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	3.33	Buy	$6.17	578.40% Upside
BHST BioHarvest Sciences	3.00	Buy	$13.67	91.95% Upside
ESLA Estrella Immunopharma	3.00	Buy	$16.00	1,726.48% Upside
KRRO Korro Bio	3.29	Buy	$102.43	669.04% Upside

Current Analyst Ratings Breakdown

Latest ESLA, KRRO, ATOS, and BHST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
5/29/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
5/5/2025	BHST BioHarvest Sciences	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
4/21/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25
4/16/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.57 per share	N/A
BHST BioHarvest Sciences	$25.19M	4.64	N/A	N/A	$0.08 per share	89.00
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	$0.12 per share	N/A
KRRO Korro Bio	$4.82M	25.94	N/A	N/A	$17.12 per share	0.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-33.90%	-31.53%	8/11/2025 (Estimated)
BHST BioHarvest Sciences	-$12.91M	-$0.50	N/A	N/A	N/A	-31.30%	-307.04%	-33.21%	8/14/2025 (Estimated)
ESLA Estrella Immunopharma	-$7.31M	-$0.26	N/A	∞	N/A	N/A	-1,132.38%	-273.91%	N/A
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)

Latest ESLA, KRRO, ATOS, and BHST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	KRRO Korro Bio	-$2.54	N/A	N/A	N/A	$0.41 million	N/A
8/11/2025	Q2 2025	ATOS Atossa Genetics	-$0.06	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	BHST BioHarvest Sciences	-$0.15	-$0.13	+$0.02	-$0.13	$8.93 million	$7.64 million
5/13/2025	Q1 2025	ATOS Atossa Genetics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
BHST BioHarvest Sciences	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	12.67	12.67
BHST BioHarvest Sciences	N/A	0.51	0.30
ESLA Estrella Immunopharma	N/A	0.22	0.22
KRRO Korro Bio	N/A	9.41	9.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
BHST BioHarvest Sciences	N/A
ESLA Estrella Immunopharma	0.35%
KRRO Korro Bio	13.18%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	8.70%
BHST BioHarvest Sciences	N/A
ESLA Estrella Immunopharma	55.10%
KRRO Korro Bio	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	129.17 million	117.93 million	Optionable
BHST BioHarvest Sciences	N/A	16.42 million	N/A	N/A
ESLA Estrella Immunopharma	N/A	36.17 million	16.24 million	Not Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data

ESLA, KRRO, ATOS, and BHST Headlines

Recent News About These Companies

Korro Bio, Inc. (KRRO) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by Analysts

June 28, 2025 | marketbeat.com

Korro to Participate in Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veracyte (VCYT), Schrodinger (SDGR) and Korro Bio (KRRO)

May 14, 2025 | theglobeandmail.com

Korro Bio to Cut 20% of Workforce

May 7, 2025 | marketwatch.com

Korro Bio to Cut 20% of Workforce

May 7, 2025 | marketwatch.com

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025 | globenewswire.com

Cantor Fitzgerald Initiates Coverage of Korro Bio (KRRO) with Overweight Recommendation

April 30, 2025 | msn.com

Chardan Capital Initiates a Buy Rating on Korro Bio (KRRO)

April 17, 2025 | markets.businessinsider.com

Korro Bio initiated with a Buy at Chardan

April 17, 2025 | markets.businessinsider.com

Chardan Capital Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation

April 17, 2025 | msn.com

Piper Sandler Sticks to Their Buy Rating for Korro Bio (KRRO)

April 11, 2025 | markets.businessinsider.com

Korro Bio appoints Loic Vincent as Chief Scientific Officer

April 2, 2025 | markets.businessinsider.com

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

April 1, 2025 | globenewswire.com

Korro Bio: Promising Early Stage RNA Editing Company

March 28, 2025 | seekingalpha.com

Korro Bio Reports 2024 Financial Results and Progress

March 20, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Korro Bio (KRRO)

March 20, 2025 | markets.businessinsider.com

Korro Bio, Inc.: Korro Reports Full Year 2024 Financial Results and Provides Business Updates

March 19, 2025 | finanznachrichten.de

Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth?

March 19, 2025 | uk.finance.yahoo.com

RBC Capital Remains a Buy on Korro Bio (KRRO)

March 19, 2025 | markets.businessinsider.com

Korro Bio price target lowered to $95 from $105 at RBC Capital

March 19, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

2 Under the Radar Space & Defense Stocks With Huge Potential
By Leo Miller | July 1, 2025
View 2 Under the Radar Space & Defense Stocks With Huge Potential
Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
By Sam Quirke | June 30, 2025
View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
By Dan Schmidt | July 2, 2025
View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
Tesla Stock Could Accelerate on New EV Tax Legislation
By Gabriel Osorio-Mazilli | July 9, 2025
View Tesla Stock Could Accelerate on New EV Tax Legislation

ESLA, KRRO, ATOS, and BHST Company Descriptions

Atossa Genetics NASDAQ:ATOS

$0.91 -0.01 (-0.63%)

As of 12:40 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

BioHarvest Sciences NASDAQ:BHST

$7.12 -0.06 (-0.84%)

As of 10:52 AM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Estrella Immunopharma NASDAQ:ESLA

$0.88 +0.03 (+2.95%)

As of 12:29 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Korro Bio NASDAQ:KRRO

$13.32 +0.66 (+5.21%)

As of 12:40 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time